Can HS-CRP levels predict the number and severity of target organ damage in essential hypertension?

Basit Öğe Kaydı
dc.contributor.authorOzerkan, F
dc.contributor.authorAkyuz, S
dc.contributor.authorOzdogan, O
dc.contributor.authorKirilmaz, B
dc.contributor.authorOnder, MR
dc.date.accessioned2019-10-27T18:57:45Z
dc.date.available2019-10-27T18:57:45Z
dc.date.issued2005
dc.departmentEge Üniversitesien_US
dc.description15th European Meeting on Hypertension -- JUN 17-21, 2005 -- Milan, ITALYen_US
dc.description.sponsorshipEuropean Soc Hypertens, AstraZeneca, Bristol-Myers Squibb Co, Boehringer Ingelheim, MSD, NOVARTIS, RECORDATI, SANKYO, Sanofi Aventis, Bayer Healthcare AG, Pfizer Inc, Solvay Pharmaceut GmbHen_US
dc.identifier.endpageS79en_US
dc.identifier.issn0263-6352
dc.identifier.startpageS79en_US
dc.identifier.urihttps://hdl.handle.net/11454/37365
dc.identifier.volume23en_US
dc.identifier.wosWOS:000230639800270en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal of Hypertensionen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleCan HS-CRP levels predict the number and severity of target organ damage in essential hypertension?en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu